CN113317998A - Anti-aging component for promoting collagen circulation and application thereof - Google Patents
Anti-aging component for promoting collagen circulation and application thereof Download PDFInfo
- Publication number
- CN113317998A CN113317998A CN202110643269.1A CN202110643269A CN113317998A CN 113317998 A CN113317998 A CN 113317998A CN 202110643269 A CN202110643269 A CN 202110643269A CN 113317998 A CN113317998 A CN 113317998A
- Authority
- CN
- China
- Prior art keywords
- rosmarinic acid
- collagen
- composition
- circulation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 35
- 108010035532 Collagen Proteins 0.000 title claims abstract description 35
- 229920001436 collagen Polymers 0.000 title claims abstract description 35
- 230000001737 promoting effect Effects 0.000 title claims abstract description 10
- 230000003712 anti-aging effect Effects 0.000 title abstract description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical group C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims abstract description 102
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims abstract description 50
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims abstract description 50
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000000419 plant extract Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 7
- 230000009759 skin aging Effects 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 102100025351 C-type mannose receptor 2 Human genes 0.000 description 12
- 101000576898 Homo sapiens C-type mannose receptor 2 Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 11
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 11
- 229930002330 retinoic acid Natural products 0.000 description 11
- 239000000284 extract Substances 0.000 description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 9
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 9
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 9
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 9
- 235000011576 oleuropein Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 229940100460 peg-100 stearate Drugs 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 2
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- AMUTYVGRCVFCCD-UHFFFAOYSA-N 5,6-diaminopyridine-3-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CN=C1N AMUTYVGRCVFCCD-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- -1 Hydroxy phenyl methyl Chemical group 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OUZOBPPZPCBJAR-UHFFFAOYSA-N 14-methylpentadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C OUZOBPPZPCBJAR-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010013050 Endo180 Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical class CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical group OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001296 salvia officinalis l. Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 201000008558 xeroderma pigmentosum group G Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses an anti-aging component for promoting collagen circulation and application thereof; the component is rosmarinic acid or plant extract containing rosmarinic acid.
Description
Technical Field
The invention relates to the field of daily chemical industry, in particular to application of rosmarinic acid in promoting collagen circulation.
Background
Skin aging resistance is the core appeal of consumers to cosmetics. Signs of skin aging include wrinkles, fine lines, loss of elasticity, laxity, and the like. Environmental factors are considered to be the most important cause for accelerating skin aging, and about 80% of skin aging is caused by environmental factors, including UV, visible light, air pollution, cigarette, etc. From the viewpoint of skin structure, the dermal layer is located between the epidermal layer and the subcutaneous adipose tissue. The biological macromolecules filled in the dermis layer are called extracellular stroma and provide support and elasticity for the skin. Collagen is the largest constituent of the extracellular matrix, and accounts for about 75% of the dry weight of the skin. The skin is wrinkled, loose and loses elasticity due to the fact that the collagen of the dermis layer is damaged by the pressure of oxidation pressure, inflammation injury and the like caused by environmental factors in the skin. Fibroblasts in the dermis can synthesize a variety of collagens, but with age, the fibroblasts have a significantly reduced ability to synthesize collagen. For example, James Varani et al found a 68% reduction in newly synthesized specific collagen in the skin of older groups over 80 years of age compared to younger groups between 18 and 29 years of age. Therefore, repairing collagen is one of the important pathways for delaying or improving skin aging. Repair glue in the prior artThe strategy of the proprotein is mainly focused on: protecting skin collagen and promoting the generation of new collagen. For example, chlorella extract from Codif (Dermochlorella D) can prevent collagen degradation; extract of Hibiscus alpina of Sederma (Majesteem)TM) Can promote the synthesis of new collagen; palmitoyl tripeptide-5 of DSM
Not only can protect collagen, but also can promote the synthesis of new collagen.
Mannose Receptor C2 (manose Receptor C type 2, MRC2) is a transmembrane glycoprotein on fibroblasts, responsible for internalizing extracellular collagen into fibroblasts, and then degraded into essential amino acids by intracellular lysosomes; these amino acids can be reused by fibroblasts to synthesize new collagen. Joong Hyun Shim et al found that UVA irradiation decreased the expression of MRC2 on fibroblasts, resulting in a decrease in the ability of fibroblasts to internalize extracellular collagen, and ultimately decreased the synthesis of new collagen. While the authors have also found that all-trans retinoic acid (ATRA) can improve UVA-reduced MRC 2. However, all-trans retinoic acid is phototoxic, is very easily degraded and can cause skin irritation.
Therefore, there is an urgent need in the art to find a more natural and safe solution to repair UVA-damaged MRC2, aiding in the internalization and circulation of collagen.
Disclosure of Invention
The invention aims to provide a method for safely promoting collagen circulation.
In a first aspect of the present invention, there is provided a use of rosmarinic acid or a plant extract containing rosmarinic acid for preparing a composition for promoting collagen circulation.
In another embodiment, rosmarinic acid is included in an amount of 0.01 to 100 wt%, based on the total weight of the composition.
In another embodiment, the composition is a dermatological product.
In another embodiment, the composition comprises rosmarinic acid or a plant extract containing rosmarinic acid and a cosmetically acceptable carrier.
In another embodiment, the product form is selected from a solution, gel, cream, liniment, microemulsion spray, suspension or emulsion.
In another embodiment, the concentration of rosmarinic acid in the composition in liquid form is 0.01-1.0 mg/mL.
In a second aspect of the present invention, there is provided a use of rosmarinic acid or a plant extract containing rosmarinic acid for preparing a composition for anti-skin aging.
Accordingly, the present invention provides a more natural and safe solution to remediate UVA-damaged MRC2, aiding in the internalization and circulation of collagen.
Drawings
FIG. 1 shows the effect of each substance in the experimental examples on the promotion of MCR2 expression on fibroblasts.
Detailed Description
The research of the inventor finds that the rosmarinic acid or the extract containing the rosmarinic acid can recover MCR2 expression of skin which is reduced on fibroblasts by ultraviolet irradiation (UVA), thereby promoting collagen circulation and playing a role in resisting skin aging. On the basis of this, the present invention has been completed.
As used herein, "Rosmarinic acid" or "Rosmarinic acid" are used interchangeably and refer to a polyphenolic molecule that is a hydroxycinnamic acid derivative. The structure is shown as the following formula I:
as used herein, "rosmarinic acid-containing extract" or "rosmarinic acid-containing extract" are used interchangeably and refer to a mixture obtained by an extraction process from plants of the family lithospermaceae (Boraginaceae) and/or labiatae (Lamiaceae), including, but not limited to, rosemary, sage, lavender, thyme, peppermint, basil, perilla, lemon balm, and the like. The extraction process includes, but is not limited to, solvent extraction, ultrasonic extraction, supercritical fluid extraction, and the like.
As used herein, "circulation of collagen" means that extracellular collagen enters fibroblasts through MRC2 receptors on the fibroblasts, and the collagen is cleaved into basic peptides and amino acids by intracellular lysozymes to construct new collagen; this is a cycle from the breakdown of old collagen to the production of new collagen. MRC2 is a very important pathway in collagen circulation and has been reported in a large number of documents. Once MRC2 is disrupted or inhibited, collagen circulation is blocked. See "Shim, Journal Hyun, et al," Reduced collagen intercalation, vision-reduction of MRC2 expression by UVA irradiation and bits recovery by all-trans extraction acid, "Journal of diagnostic science 73.2 (2014)" and "Tang, Stefanie, et al," UV-mediated visualization of the intracellular diagnostic reagent, Endo180, constraints of extracellular diagnostic reagent in photographic skin "Journal of diagnostic science 70.1 (2013)"
In this context, "fibroblasts" are the major cellular components of loose connective tissue, the most prominent cell type of the dermis, with cells in the shape of fusiform or flat stars with protrusions.
The term "effective amount" is intended to be used for the purpose of improving epidermal senescence, such an amount being capable of promoting and assisting the expression of MRC2 on fibroblasts after a suitable period of use.
"composition" refers to a composition that, when applied to an individual (typically a human), is capable of penetrating the skin to induce the desired epidermal aging-improving effect.
As used herein, the term "cosmetically acceptable carrier" refers to a carrier that allows a cosmetic or personal care product to be applied, including various excipients and diluents, which are not themselves essential active ingredients, and which do not have undue toxicity after application. Suitable carriers are well known to those of ordinary skill in the art. A sufficient discussion of cosmetically acceptable excipients can be found in the cosmetic hygiene specifications 2015 edition. Such carriers may include humectants, emulsifiers, thickeners, chelating agents, emollients, and the like in the composition. Such as, but not limited to, water, potassium hydroxide, 1, 2-hexanediol, p-hydroxyacetophenone, methylparaben, phenoxyethanol, ethylhexyl glycerol, butylene glycol, panthenol, dipotassium glycyrrhizinate, arginine, glycerol, sodium hyaluronate, propylene glycol, hexylene glycol, glyceryl stearate/PEG-100 stearate, glyceryl caprylate, xanthan gum, betaine, hydroxyethyl cellulose, carbomer, disodium EDTA, isocetyl palmitate, isooctyl palmitate, ethylhexyl palmitate, cetostearyl alcohol, dimethicone, citric acid or a salt thereof, behenyl alcohol polyether, ceteth alcohol, pentaerythritol tetrakis (ethylhexanoate), squalane, cetyl alcohol ethylhexanoate, and the like.
The term "administering" as used herein means directly administering a comparable amount of rosmarinic acid or an extract containing rosmarinic acid.
The terms "individual" or "individual" and the like are used herein to refer to a person who can receive the rosmarinic acid or rosmarinic acid-containing extract and/or method on the skin.
As used herein, "room temperature" means 15-45 deg.C, preferably 20-35 deg.C.
In the case where the expression of MCR2 is reduced on fibroblasts by ultraviolet irradiation (UVA), the present invention provides a method of improving or increasing the expression of MCR2 by administering rosmarinic acid or an extract containing rosmarinic acid. Administration is liquid, wherein the concentration of rosmarinic acid is between 0.01-1.0mg/mL, such as, but not limited to, 0.01-0.5mg/mL, 0.015-0.2mg/mL, 0.02-0.1mg/mL, 0.02-0.05mg/mL, and the like.
Further, the present invention provides a composition comprising rosmarinic acid or an extract containing rosmarinic acid and a cosmetically acceptable carrier, thereby obtaining various cosmetics or personal care products applicable to human skin, including, but not limited to, a makeup cream, a sunscreen cream, a cream, an eye cream, an emulsion, a essence, a lotion, a gel, etc.
The cosmetic or personal care product provided by the invention contains 0.005-0.5 wt% of rosmarinic acid or rosmarinic acid-containing extract, such as, but not limited to, 0.008-0.3 wt%, 0.02-0.2 wt%, etc., based on the total weight of the product.
In some embodiments of the present invention, the cosmetic or personal care product is obtained by combining the compositions provided herein with a cosmetically acceptable carrier that can be used to form the aqueous phase. The cosmetically acceptable carrier that may be used to form the aqueous phase includes, but is not limited to, one or more of methylparaben, ethylhexylglycerin, butylene glycol, glycerin, sodium hyaluronate, and water.
In one embodiment of the present invention, the composition provided by the present invention is mixed with water to form an aqueous phase, and then mixed with a cosmetically acceptable carrier for the oil phase and emulsified to obtain the cosmetic or personal care product. Preferably, the cosmetic or personal care product may be formed by adding preservatives, perfumes, etc. after emulsification and cooling to room temperature.
In another embodiment of the present invention, the cosmetic or personal care product is obtained by adding the composition provided by the present invention after mixing and emulsifying the cosmetically acceptable carrier of the oil phase and the cosmetically acceptable carrier of the water phase. Preferably, the cosmetic or personal care product may be formed by adding the composition provided by the present invention after emulsification and cooling to room temperature.
In another embodiment of the invention, the cosmetic or personal care product may also be obtained by adding the composition provided by the present invention after homogenization of the aqueous cosmetically acceptable carrier. Preferably, the cosmetic or personal care product may be formed by adding the composition provided by the present invention after homogenization and cooling to room temperature.
In some embodiments of the invention, the cosmetically acceptable carrier used to form the oil phase includes, but is not limited to, one or more of glyceryl stearate, glyceryl monostearate, glyceryl stearate/PEG-100 stearate complex, isomeric hexadecanes, isooctyl palmitate, ethylhexyl palmitate, cetearyl alcohol, behenyl alcohol, cetostearyl alcohol, ceteth, dimethicone, pentaerythritol tetrakis (ethylhexanoate), squalane, cetyl ethylhexanoate petrolatum, shea butter, squalane, lecithin.
Although numerical ranges and parameters setting forth the broad scope of the invention are approximate, the values set forth in the specific examples are presented as precisely as possible. Any numerical value, however, inherently contains certain standard deviations found in their respective testing measurements. As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "about" means that the actual value falls within the acceptable standard error of the mean, as considered by those skilled in the art. Except in the experimental examples, or where otherwise expressly indicated, it is to be understood that all ranges, amounts, values and percentages herein used (e.g., to describe amounts of materials, length of time, temperature, operating conditions, quantitative ratios, and the like) are to be modified by the word "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, these numerical parameters are to be understood as meaning the number of significant digits recited and the number resulting from applying ordinary carry notation.
Unless defined otherwise herein, the scientific and technical terms used herein have the same meaning as is commonly understood and used by one of ordinary skill in the art. Furthermore, as used herein, the singular tense of a noun, unless otherwise conflicting with context, encompasses the plural form of that noun; the use of plural nouns also covers the singular form of such nouns.
To make the features and effects of the present invention comprehensible to those skilled in the art, general description and definitions are made below with reference to terms and expressions mentioned in the specification and claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The theory or mechanism described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, i.e., the present disclosure may be practiced without limitation to any particular theory or mechanism.
All features defined herein as numerical ranges or percentage ranges, such as values, amounts, levels and concentrations, are for brevity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to cover and specifically disclose all possible subranges and individual numerical values (including integers and fractions) within the range.
The features mentioned above with reference to the invention, or the features mentioned with reference to the embodiments, can be combined arbitrarily. All features disclosed in this specification may be combined in any combination, provided that there is no conflict between such features and the combination, and all possible combinations are to be considered within the scope of the present specification. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, the features disclosed are merely generic examples of equivalent or similar features.
The main advantages of the invention are: the composition provided by the invention can effectively improve expression of MRC2 inhibited by UVA.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. All percentages, ratios, proportions, or parts are by weight unless otherwise specified. The weight volume percentage units in the present invention are well known to those skilled in the art and refer to, for example, the weight of solute in a 100 ml solution. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
Test examples
Rosmarinic acid promotes and improves MCR2 expression in fibroblasts
Material
The test system comprises:
the cells used in this test were human fibroblasts (batch No.: Fb19070303) obtained by cell primary culture and subculture from Guangdong Boxi Biotech Ltd.
The main reagents are as follows:
DMEM culture solution (GIBCO), fetal bovine Serum (SIJIQING), PBS (Solibao), MTT (Sigma), DMSO (Sigma), RNAioso Plus (Takara), reverse transcription kit (Takara), fluorescent dye (Takara)
The main equipment is as follows:
CO2 incubator (Thermo, 150i), clean bench (SW-CJ-1F, Antai Suzhou), microplate reader (BioTek, Epoch), fluorescence quantitative PCR instrument (BioRad, CFX96), general PCR instrument (Bori, TC-XP-G)
All-trans retinoic acid (ATRA) was purchased from Guangdong Boxi Biotech Ltd
Rosmarinic acid was purchased from Changsha Shanhe biological Co., Ltd
Oleuropein was purchased from Doctorius Biotech Ltd
Method
Cell inoculation:
by 2.0X 105The fibroblast cells were inoculated into 6-well plates at a cell/well inoculation density and an incubator (37 ℃ C., 5% CO)2) And incubated overnight.
Preparing a working solution: (the composition of the culture solution was 90% DMEM and 10% fetal bovine serum)
Blank control: wherein only cells cultured in a culture medium were used without adding any of the following test components
Positive control: all-trans retinoic acid (ATRA) was dissolved in the culture medium so that the concentration of ATRA was 100. mu.M
0.035mg/mL rosmarinic acid: dissolving rosmarinic acid in the culture solution to make the concentration of rosmarinic acid 0.035mg/mL
0.07mg/mL rosmarinic acid: dissolving rosmarinic acid in the culture solution to make the concentration of rosmarinic acid 0.07mg/mL
0.035mg/mL oleuropein: oleuropein is dissolved in the culture solution to make the concentration of oleuropein 0.035mg/mL
0.07mg/mL oleuropein: oleuropein is dissolved in the culture medium to make the concentration of oleuropein 0.07mg/mL
Administration: when the cell plating rate in the 6-well plate reaches 40% -60%, the blank control group, the positive control group, the 0.035mg/mL rosmarinic acid group, the 0.07mg/mL rosmarinic acid group, the 0.035mg/mL oleuropein group and the 0.07mg/mL oleuropein group are respectively administrated by 2mL of the prepared working solution in each well, and each group is provided with 3 multiple wells. After completion of the administration, the 6-well plate was placed in an incubator (37 ℃ C., 5% CO)2) And culturing for 24 h.
UVA irradiation: after PBS washing of the cells, the groups irradiated with UVA were subjected to 30J/cm according to experimental groups2UVA irradiation of (1).
Collecting cells: after 24h incubation, the cells were washed twice with 1 mL/well PBS, 1mL of RNAioso Plus was added to each well, and the lysed cells were aspirated and collected.
And (3) gene expression detection: extracting RNA, carrying out reverse transcription to cDNA, carrying out fluorescent quantitative PCR detection, and calculating the result by adopting a 2-delta CT method.
And (4) analyzing results: the statistical analysis of t-test is adopted among groups, P < 0.05 indicates that the difference is obvious, and P <0.01 indicates that the difference is extremely obvious.
Results
See figure 1.
On fibroblasts, UVA irradiation reduced the gene expression (ordinate) of MCR2, while all-trans retinoic acid (ATRA) repaired the expression of MCR2, rosmarinic acid significantly improved UVA-reduced MCR2(p <0.01) at different concentrations (0.07mg/ml &0.035mg/ml), with comparable effects to all-trans retinoic acid.
UVA triggers intracellular oxidative stress, however oleuropein does not significantly improve the expression of MCR2 even though oleuropein has strong antioxidant capacity, and thus rosmarinic acid may not be responsible for the repair of MCR 2.
The results show that UVA irradiation inhibits MRC2, while rosmarinic acid can increase UVA inhibition of MRC2, i.e. repair collagen circulation.
Use example 1
Toner
| Raw materials | Wt％ | Wt％ |
| Deionized water | to 100 | to 100 |
| Glycerol | 3 | 3 |
| Butanediol | 4 | 4 |
| Xanthan gum | 0.2 | 0.2 |
| Hyaluronic acid sodium salt | 0.01 | 0.01 |
| Rosmarinic acid | 0.01 | 0.05 |
| Hydroxy phenyl methyl ester | 0.05 | 0.05 |
| Ethyl hexyl glycerol | 0.1 | 0.1 |
Use example 2
Essence of plant
| Raw materials | Wt％ | Wt％ |
| Deionized water | to 100 | to 100 |
| Betaine | 0.5 | 0.5 |
| Glycerol | 5 | 5 |
| Hyaluronic acid sodium salt | 0.05 | 0.05 |
| Butanediol | 4 | 4 |
| Xanthan gum | 0.5 | 0.5 |
| Hydroxyethyl cellulose | 0.15 | 0.15 |
| Rosmarinic acid | 0.03 | 0.1 |
| Hexanediol | 0.4 | 0.4 |
| Glycerol caprylate | 0.4 | 0.4 |
Use example 3
Cream
| Raw materials | Wt％ | Wt％ |
| Deionized water | to 100 | to 100 |
| Carbomer | 0.3 | 0.3 |
| EDTA2 Na | 0.02 | 0.02 |
| Glycerol | 5 | 5 |
| Butanediol | 3 | 3 |
| Polydimethylsiloxane | 5 | 5 |
| Ethyl hexyl palmitate | 3 | 3 |
| Cetostearyl alcohol | 2 | 2 |
| Glycerol monostearate | 1.5 | 1.5 |
| Glycerol stearate/PEG-100 stearate | 2 | 2 |
| Potassium hydroxide | 0.15 | 0.15 |
| Rosmarinic acid | 0.05 | 0.15 |
| Phenoxyethanol | 0.3 | 0.3 |
| Ethyl hexyl glycerol | 0.1 | 0.1 |
The foregoing is merely a preferred embodiment of the invention and is not intended to limit the scope of the invention, which is defined by the claims appended hereto, and any other technical entity or method that is encompassed by the claims as broadly defined herein, or equivalent variations thereof, is contemplated as being encompassed by the claims.
Claims (7)
1. Use of rosmarinic acid or plant extract containing rosmarinic acid in preparing composition for promoting collagen circulation is provided.
2. The use of claim 1, wherein rosmarinic acid is included in an amount of 0.01 to 100 wt%, based on the total weight of the composition.
3. The use of claim 1, wherein the composition is a dermatological product.
4. The use according to claim 3, wherein the composition comprises rosmarinic acid or a plant extract containing rosmarinic acid and a cosmetically acceptable carrier.
5. The use according to claim 3, wherein the product form is selected from a solution, gel, cream, liniment, microemulsion spray, suspension or emulsion.
6. The use according to any one of claims 1 to 5, wherein the concentration of rosmarinic acid in the composition in liquid form is 0.01 to 1.0 mg/mL.
7. Use of rosmarinic acid or plant extract containing rosmarinic acid in preparing composition for resisting skin aging is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110643269.1A CN113317998A (en) | 2021-06-09 | 2021-06-09 | Anti-aging component for promoting collagen circulation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110643269.1A CN113317998A (en) | 2021-06-09 | 2021-06-09 | Anti-aging component for promoting collagen circulation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113317998A true CN113317998A (en) | 2021-08-31 |
Family
ID=77420261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110643269.1A Pending CN113317998A (en) | 2021-06-09 | 2021-06-09 | Anti-aging component for promoting collagen circulation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113317998A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300421A (en) * | 2021-09-23 | 2022-11-08 | 上海宜侬生物科技有限公司 | Ginseng ferment, application of ginseng ferment in repairing mannose receptor C2 and skin care product |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017128538A (en) * | 2016-01-21 | 2017-07-27 | 丸善製薬株式会社 | Endo180 production promoter |
| CN110664671A (en) * | 2018-07-02 | 2020-01-10 | 华东师范大学 | Plant extract composition and application thereof in sunscreen, after-sun repair, photoaging prevention and whitening cosmetics |
-
2021
- 2021-06-09 CN CN202110643269.1A patent/CN113317998A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017128538A (en) * | 2016-01-21 | 2017-07-27 | 丸善製薬株式会社 | Endo180 production promoter |
| CN110664671A (en) * | 2018-07-02 | 2020-01-10 | 华东师范大学 | Plant extract composition and application thereof in sunscreen, after-sun repair, photoaging prevention and whitening cosmetics |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300421A (en) * | 2021-09-23 | 2022-11-08 | 上海宜侬生物科技有限公司 | Ginseng ferment, application of ginseng ferment in repairing mannose receptor C2 and skin care product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3756838B2 (en) | Topical skin preparation | |
| JP4299374B2 (en) | Cell activator and its application | |
| JP2011088845A (en) | Involucrin expression inhibitor | |
| CN113317998A (en) | Anti-aging component for promoting collagen circulation and application thereof | |
| JP4027949B2 (en) | Hair nourishing agent | |
| JP5959995B2 (en) | Skin wrinkle formation preventive / improving agent | |
| JP2016027034A (en) | External composition | |
| JP5117092B2 (en) | Moisturizer, anti-aging agent, whitening agent, antioxidant, slimming agent, treatment agent, arginase activity promoter and external preparation for skin | |
| CN108969438A (en) | Contain bletilla striata extract, white flower papaya extractives and anti-wrinkle cream of Herba Agrimoniae extract and preparation method thereof | |
| JP5312731B2 (en) | Topical skin preparation | |
| TWI687237B (en) | Use of extract of victoria cruziana for inducing expression of keratin gene and hyaluronan synthase 2 gene, and enhancing moisture-retaining capacity of skin | |
| TWI694829B (en) | Use of extract of selaginella tamariscina for inducing expression of keratin gene, hyaluronan synthase gene and filaggrin gene, enhancing mitochondrial activity of cells, enhancing moisture-retaining capacity of skin, and anti-aging | |
| KR102162935B1 (en) | Cosmetic composition for skin suppression, skin moisturizing, anti-acne or sebum controlling | |
| JP2011088854A (en) | Involucrin expression inhibitor | |
| JP5383001B2 (en) | Skin preparations, moisturizers, anti-aging agents, antioxidants, anti-inflammatory agents, whitening agents, and slimming agents | |
| CN113081878B (en) | Combination for synergistically promoting synthesis of hyaluronic acid in skin and application thereof | |
| CN113143782B (en) | Cosmetic composition for improving epidermal aging and application thereof | |
| JP2007277100A (en) | Humectant, cell activator, dermal fibroblast activator, epidermal cell activator, collagen production accelerator, antioxidant, anti-aging agent, beautifully whitening agent or melanin production inhibitor | |
| TWI743414B (en) | Use of anethum graveolens seed extracts for decreasing brain nerve cell damage and slowing down neuronal apoptosis | |
| KR20110101727A (en) | Composition for improving skin wrinkle | |
| CH706016A2 (en) | Cosmetic composition acting on stem cells of e.g. epidermis and dermis, useful e.g. for treating or preventing skin aging signs, comprises pentapeptide, peptide fraction of Pisum sativum, and extract of Laminaria digitata alga and carrier | |
| CN114010563A (en) | Component with brightening and anti-aging effects and application thereof | |
| KR20080069816A (en) | Composition for improving wrinkle and elasticity | |
| JP2003342156A (en) | External preparation for skin for prevention of aging | |
| KR20110101720A (en) | Composition for improving skin wrinkle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210831 |
|
| WD01 | Invention patent application deemed withdrawn after publication |